Guillain-Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
10
05
2022
pubmed:
9
6
2022
medline:
7
7
2022
entrez:
8
6
2022
Statut:
ppublish
Résumé
The concern surrounding the association between Guillain-Barré syndrome (GBS) and vaccination has increased with the widespread use of COVID-19 vaccines. The aim of this study was to assess the potential association of GBS with mRNA-based or adenovirus-vectored COVID-19 vaccines. Reports of GBS associated with mRNA-based or adenovirus-vectored COVID-19 vaccines were extracted from the WHO pharmacovigilance database, exposure data from the Our World in Data website, and the background rates of GBS from published data. For countries contributing to VigiBase and with available data on COVID-19 vaccine exposure, reporting rates were estimated and observed-to-expected (OE) analyses were performed. A total of 2499 cases were included: 1157 (46.3%) cases with adenovirus-vectored COVID-19 vaccines and 1342 (53.7%) with mRNA-based COVID-19 vaccines. The male-to-female sex ratio was 1.09 and the median (IQR) age was 57 (45-66) years. The reporting rates (95% CI) per 100,000 person-years within the 42-day window were 5.57 (5.13-6.03) for adenovirus-vectored COVID-19 vaccines and 1.39 (1.31-1.47) for mRNA-based COVID-19 vaccines, while the background incidence was 1.2-3.1 per 100,000 person-years. For mRNA-based COVID-19 vaccines, the OE ratio was <1 for both time windows in all European countries and slightly elevated for the 21-day window in the USA. For adenovirus-vectored COVID-19 vaccines, the OE ratio was consistently > 2.0 for all countries. Sensitivity analyses minimally altered these results. These findings suggest both the absence of safety concern for GBS with mRNA-based COVID-19 vaccines and an increased risk with adenovirus-vectored COVID-19 vaccines. Back to top.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
The concern surrounding the association between Guillain-Barré syndrome (GBS) and vaccination has increased with the widespread use of COVID-19 vaccines. The aim of this study was to assess the potential association of GBS with mRNA-based or adenovirus-vectored COVID-19 vaccines.
METHODS
METHODS
Reports of GBS associated with mRNA-based or adenovirus-vectored COVID-19 vaccines were extracted from the WHO pharmacovigilance database, exposure data from the Our World in Data website, and the background rates of GBS from published data. For countries contributing to VigiBase and with available data on COVID-19 vaccine exposure, reporting rates were estimated and observed-to-expected (OE) analyses were performed.
RESULTS
RESULTS
A total of 2499 cases were included: 1157 (46.3%) cases with adenovirus-vectored COVID-19 vaccines and 1342 (53.7%) with mRNA-based COVID-19 vaccines. The male-to-female sex ratio was 1.09 and the median (IQR) age was 57 (45-66) years. The reporting rates (95% CI) per 100,000 person-years within the 42-day window were 5.57 (5.13-6.03) for adenovirus-vectored COVID-19 vaccines and 1.39 (1.31-1.47) for mRNA-based COVID-19 vaccines, while the background incidence was 1.2-3.1 per 100,000 person-years. For mRNA-based COVID-19 vaccines, the OE ratio was <1 for both time windows in all European countries and slightly elevated for the 21-day window in the USA. For adenovirus-vectored COVID-19 vaccines, the OE ratio was consistently > 2.0 for all countries. Sensitivity analyses minimally altered these results.
CONCLUSIONS
CONCLUSIONS
These findings suggest both the absence of safety concern for GBS with mRNA-based COVID-19 vaccines and an increased risk with adenovirus-vectored COVID-19 vaccines. Back to top.
Identifiants
pubmed: 35676452
doi: 10.1007/s40261-022-01164-4
pii: 10.1007/s40261-022-01164-4
pmc: PMC9177406
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-592Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Priority list of Adverse Events of Special Interest: Covid 19. Updated December 23, 2020. https://brightoncollaboration.us/priority-list-aesi-covid/ . Accessed 31 Oct 2021.
Principi N, Esposito S. Vaccine-preventable diseases, vaccine and Guillain–Barré syndrome. Vaccine. 2019;37:5544–50. https://doi.org/10.1016/j.vaccine.2018.05.119 .
doi: 10.1016/j.vaccine.2018.05.119
pubmed: 29880241
Petras M, Lesna IK, Danova J, Celko AM. Is an increased risk of developing Guillain–Barré syndrome associated with seasonal Influenza vaccination? A systematic review and meta-analysis. Vaccines (Basel). 2020;8:150. https://doi.org/10.3390/vaccines8020150 .
doi: 10.3390/vaccines8020150
pmcid: 7349742
Stowe J, Andrews N, Miller E. Do vaccines trigger neurological diseases? Epidemiological evaluation of vaccination and neurological diseases using examples of multiple sclerosis, Guillain–Barré syndrome and narcolepsy. CNS Drugs. 2020;34:1–8. https://doi.org/10.1007/s40263-019-00670-y .
doi: 10.1007/s40263-019-00670-y
pubmed: 31576507
Chen Y, Zhang J, Chu X, Xu Y, Ma F. Vaccines and the risk of Guillain–Barré syndrome. Eur J Epidemiol. 2020;35:3663–70. https://doi.org/10.1007/s10654-019-00596-1 .
doi: 10.1007/s10654-019-00596-1
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–90. https://doi.org/10.1056/NEJMoa2110475 .
doi: 10.1056/NEJMoa2110475
pubmed: 34432976
Klok FA, Pai M, Huisman MV, Makris M. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol. 2022;9(1):e73–80. https://doi.org/10.1016/S2352-3026(21)00306-9 .
doi: 10.1016/S2352-3026(21)00306-9
pubmed: 34774202
pmcid: 8585488
Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27:2144–53. https://doi.org/10.1038/s41591-021-01556-7 .
doi: 10.1038/s41591-021-01556-7
pubmed: 34697502
pmcid: 8629105
Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain–Barré syndrome, February–July 2021. JAMA. 2021;326:1606–13. https://doi.org/10.1001/jama.2021.16496 .
doi: 10.1001/jama.2021.16496
pubmed: 34617967
Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain–Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. https://doi.org/10.1016/j.vaccine.2010.06.003 .
doi: 10.1016/j.vaccine.2010.06.003
pubmed: 20600491
Mathieu E, Ritchie H, Ortiz-Ospina E et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5:947–53. https://doi.org/10.1038/s41562-021-01122-8 . https://ourworldindata.org/covid-vaccinations . Accessed 31 Oct 2021.
Willame C, Dodd C, Gini R, Durán CE, Thomsen RM, Lei W et al. Background rates of adverse events of special interest for monitoring COVID-19 vaccines, version 2.0, June 30, 2021. https://zenodo.org/record/5255870#.YadwNPlKiUl . Accessed 1 Dec 2021.
Delannoy A, Rudant J, Chaignot C, Bolgert F, Mikaeloff Y, Weill A. Guillain–Barre syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008–2013). Peripher Nerv Syst. 2017;22:51–8. https://doi.org/10.1111/jns.12202 .
doi: 10.1111/jns.12202
Shui IM, Rett MD, Weintraub E, et al. Guillain–Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology. 2012;39:109–15. https://doi.org/10.1159/000339248 .
doi: 10.1159/000339248
pubmed: 22846726
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96. https://doi.org/10.2165/00002018-200629050-00003 .
doi: 10.2165/00002018-200629050-00003
pubmed: 16689555
Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B. Risk of Guillain–Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf. 2014;23:1192–204. https://doi.org/10.1002/pds.3638 .
doi: 10.1002/pds.3638
pubmed: 24817531
pmcid: 4282476
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33–43. https://doi.org/10.1093/brain/awt285 .
doi: 10.1093/brain/awt285
pubmed: 24163275
Willison HJ, Jacobs BC, van Doorn PA. Guillain–Barré syndrome. Lancet. 2016;388:717–27. https://doi.org/10.1016/S0140-6736(16)00339-1 .
doi: 10.1016/S0140-6736(16)00339-1
pubmed: 26948435
Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain–Barré syndrome. Brain J Neurol. 2021;144:682–93.
doi: 10.1093/brain/awaa433
Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain–Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268:1133–70. https://doi.org/10.1007/s00415-020-10124-x .
doi: 10.1007/s00415-020-10124-x
pubmed: 32840686
Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain–Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021;28:3517–29. https://doi.org/10.1111/ene.14860 .
doi: 10.1111/ene.14860
pubmed: 33837630
Shao SC, Wang CH, Chang KC, Hung MJ, Chen HY, Liao SC. Guillain–Barre syndrome associated with COVID-19 vaccination. Emerg Infect Dis. 2021;27:3175–8. https://doi.org/10.3201/eid2712.211634 .
doi: 10.3201/eid2712.211634
pubmed: 34648420
pmcid: 8632191
Rosenblum HG, Hadler SC, Moulia D et al. Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;13;70:1094–9. https://doi.org/10.15585/mmwr.mm7032e4 .
Bouattour N, Hdiji O, Sakka S et al. Guillain–Barré syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. Neurol Sci. 2022;43(2):755–61. https://doi.org/10.1007/s10072-021-05733-x .
doi: 10.1007/s10072-021-05733-x
pubmed: 34796417
pmcid: 8601771
Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID-19: Guillain–Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13:e13426. https://doi.org/10.7759/cureus.13426 .
doi: 10.7759/cureus.13426
pubmed: 33758714
pmcid: 7978140
Kim MS, Jung SY, Ahn JG et al. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis using WHO international database. J Med Virol. 2022;94(3):1085–95. https://doi.org/10.1002/jmv.27424 .
doi: 10.1002/jmv.27424
pubmed: 34862628
pmcid: 9015469
Noseda R, Ripellino P, Ghidossi S, Bertoli R, Ceschi A. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analyses in VigiBase. Vaccines (Basel). 2021;9:1022. https://doi.org/10.3390/vaccines9091022 .
doi: 10.3390/vaccines9091022
Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–9. https://doi.org/10.1001/jama.2021.15072 .
doi: 10.1001/jama.2021.15072
pubmed: 34477808
Ben Simon SS, Potasman I, Rahamim-Cohen D. Rate of recurrent Guillain–Barre syndrome after mRNA COVID-19 vaccine BNT162b2. JAMA Neurol. 2021;78:1409–11. https://doi.org/10.1001/jamaneurol.2021.3287 .
doi: 10.1001/jamaneurol.2021.3287
Allen CA, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Radu Tanasescu R, Evans JR. Guillain–Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90:315–8. https://doi.org/10.1002/ana.26144 .
doi: 10.1002/ana.26144
pubmed: 34114269
Pegat A, Vogrig A, Khouri C, Masmoudi K, Vial T, Bernard E. Adenovirus COVID-19 vaccines and Guillain–Barré syndrome with facial paralysis. Ann Neurol. 2022;91(1):162–3. https://doi.org/10.1002/ana.26258 .
doi: 10.1002/ana.26258
pubmed: 34699065
pmcid: 8652690
García-Grimshaw M, Michel-Chávez A, Vera-Zertuche JM, et al. Guillain–Barre syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol. 2021;230:108818. https://doi.org/10.1016/j.clim.2021.108818 .
doi: 10.1016/j.clim.2021.108818
pubmed: 34358692
pmcid: 8332675
Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf. 2003;12:271–81. https://doi.org/10.1002/pds.848 .
doi: 10.1002/pds.848
pubmed: 12812006
Mahaux O, Bauchau V, van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Druf Saf. 2016;25:215–22. https://doi.org/10.1002/pds.3918 .
doi: 10.1002/pds.3918